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Since its introduction in 2000, PET/CT has become a wide-
spread and effective imaging tool for the diagnosis and man-
agement of patients with cancer. Today, over 5,000 combined
PET/CT systems are in clinical operation worldwide. As a
core component of PET/CT, PET is a highly sensitive imaging
technique capable of detecting as few as one million cancer
cells [1]. Its inherent quantitative nature enables accurate, re-
producible measurements of radiopharmaceutical uptake in
the tumour during diagnostic work-up, therapy and treatment
follow-up. Technological advances in PET imaging technolo-
gy go hand in hand with the development of highly specific
PET probes, with most of them only now being available for
on-site use.
Combined PET/CT has been shown to have exceeded the
expectations laid out in a seminal paper byWahl et al. [2], who
referred to combined imaging methods as Banatometabolic^
imaging, thus pointing to the inherent potential benefits of
combining complementary imagingmethods. Numerous stud-
ies have demonstrated the increased diagnostic accuracy of
PET/CT compared with that of either PET or CT alone. As a
result, PET/CT has become one of the most effective imaging
modalities in oncology. Clinical users and manufacturers have
also started to adopt standardized acquisition and reporting
protocols as a prerequisite for the adoption of any imaging
modality in guidelines for patient management.
Furthermore, PET/CT has shown significant promise for
reducing the cost of cancer management by improving the
accuracy of both diagnosis and staging, thereby helping to
avoid expensive, futile treatments (such as curative intent sur-
gery and radiation therapy in patients demonstrated by PET to
have advanced disease) and associated side effects. Overall,
PET/CT has the potential to increase a patient’s quality-
adjusted life years (QALYs) and reduce the cost burden over
time to the healthcare system by identifying the most appro-
priate treatment. However, the potential of PET as a tool to
help in the management of cancer patients has not yet been
reflected in the extent of its adoption. Here, we attempt to
summarize the main reasons for this observation.
Clinical evidence
One of the most widely adopted application of PET/CT is for
the preoperative staging of non-small-cell lung cancer
(NSCLC) using [18F]fluorodeoxyglucose (FDG).
Randomized clinical trials have established the the value of
PET/CT over conventional CT for the staging of NSCLC [3,
4]. More recent studies have analysed the cost-effectiveness of
PET/CT for preoperative staging of NSCLC and have dem-
onstrated that the clinical use of PET/CT for staging of the
disease leads to significant decreases in surgery and
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radiotherapy rates and an increase in chemotherapy use [5].
Cost-effectiveness analyses performed alongside randomized
clinical trials have established that PET/CT provides accurate
preoperative staging of NSCLC and its use leads to cost sav-
ings. The systematic use of PET/CT has been shown to de-
crease the number of futile thoracotomies and lower the costs
associated with lung cancer diagnosis and treatment [6, 7].
NSCLC patients receiving the most appropriate treatment
have better quality of life. Similar results from a 2-year
multicentre study on head and neck squamous cell carcinoma
follow-up have recently been published. Patients receiving
PET/CT surveillance had equal survival probability, while un-
necessary surgery and potential complications were avoided,
and its use saved £1,492 per patient for the duration of the
study [8].
PET/CT imaging is also emerging as a powerful tool for
identifying and localizing primary and recurrent prostate can-
cer. The use of PET/CT in prostate cancer has benefited from
the development of promising radiotracers, including
[11C]choline, [18F]fluorocholine, [11C]acetate, [18F]FACBC
and, recently, agents targeting prostate-specific membrane an-
tigen (PSMA) [9–11]. [11C]Choline- and [18F]fluorocholine
PET/CT are being increasingly used in the US, Europe and
Japan to detect locally recurrent and metastatic prostate can-
cer. Early clinical results suggest that the novel PSMA-
targeted radiotracers may prove even more effective [12].
Since prostate cancer is a biologically and clinically heteroge-
neous disease, ranging from indolent to aggressive forms,
PET/CT may be critical as well as cost-effective in therapy
selection and management of prostate cancer.
Hypoxic tumours are associated with an aggressive pheno-
type, therapy resistance, increased risk of metastasis, and an
overall poor prognosis [13]. PET/CT is the preferred method
for identifying tumour hypoxia due largely to its high specific-
ity and sensitivity, and quantification capabilities, so an in-
creasing number of hypoxia PET tracers are being evaluated
in the clinic. For instance, studies have shown promising re-
sults with [18F]fluoromisonidazole (FMISO) and
[18F]fluoroazomycin-arabinofuranoside (FAZA) for identify-
ing hypoxia in a variety of tumour types, including gliomas,
lung, and head and neck tumours [14]. Thus, in the future PET/
CT may help guide treatment decisions by identifying patients
who are likely to benefit from hypoxia-targeted therapy.
Moreover, there is also an interest in using PET/CT for radio-
therapy treatment planning because of its ability to identify and
delineate hypoxic areas that require a higher dose [15].
The few clinical examples discussed above show how PET/
CT can help select the appropriate cancer treatment, so that
ineffective therapies can be avoided or quickly discontinued
reducing both cost and emotional burden on the patient. PET/
CT can also be used to evaluate the effectiveness of new che-
motherapeutic agents. The costs of cancer drug development
continue to rise at an unsustainable rate and a key driver of this
escalation is the failure of experimental drugs late in the devel-
opment process [16]. PET/CT can be used to investigate the
pharmacodynamics of new drugs and to identify eventual drug
failure at earlier stages of development. This may
ultimately help to contain the costs of drug development.
Clinical trials of ineffective drugs can be stopped in a timely
fashion, an important consideration in view of the limited funds
available. Resources can be redirected to those drugs that are
validated as effective throughout all stages of drug development.
For example, iniparib was reported to be a poly(ADP-ribose)
polymerase (PARP) inhibitor with promising results for treating
patients with triple-negative breast cancer. However, recent
studies have suggested that it is not a PARP inhibitor at clinically
relevant doses in patients [17]. This resulted in the waste of
US$285 million, which could have been avoided, or greatly
reduced with the use of appropriate preclinical PET studies.
Barriers to clinical adoption
Despite the documented clinical benefits of using PET/CT for
oncology applications, there are several significant barriers to
its wider clinical adoption:
1. Clinicians referring patients for nuclear medicine exami-
nations need regular training opportunities to better value
the diagnostic information that PET/CT images can pro-
vide. The lack of anatomical resolution in PET-only im-
ages hindered fast clinical adoption of this technology
among traditional, radiology-driven medical experts in
the early period of PET development. The introduction
of integrated PET/CT systems has largely overcome this
barrier, but continued education of referring physicians is
still essential.
2. Regulation of the production of radiopharmaceuticals
varies across the world. To date, radiopharmaceuticals
are considered as full pharmaceuticals, mandating corre-
spondingly complex handling, even though any effect of
the active pharmaceutical component of a radiopharma-
ceutical is well below therapeutic levels. The increasingly
demanding regulatory requirements are a major concern
for the generally small radiopharmaceutical companies.
Innovative new radiopharmaceuticals are difficult to bring
to the clinic and the market. As a consequence, only few
industrial partners set out on this steep path.
3. PET/CT coverage policies of government agencies and
private payers are both variable and restrictive. While
coverage has been expanded in the US, it varies consid-
erably within the European Union, with Germany and
Austria promoting essentially a Bnil reimbursement^ pol-
icy for public healthcare. Large randomized clinical trials,
requested by various national health authorities, are pro-
hibitively expensive in most countries.
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Recommendations to overcome barriers to wider
adoption of PET/CT
Regulatory agencies that determine coverage policies re-
quire peer-reviewed scientific evidence to show that a
new radiopharmaceutical or technology leads to improve-
ments in patient management and health outcomes. In the
field of oncology, such evidence is generally required on a
cancer-specific and indication-specific basis. This often
creates a Bcatch 22^ scenario in which coverage cannot
be attained without evidence, but there is no viable way to
pay for the PET/CT scans to acquire the evidence without
coverage. The experience in the US may serve as an ex-
ample of how to overcome the coverage barrier. In the
US, the Centers for Medicare & Medicaid Services
(CMS) administer the federal health insurance programs
and CMS policies dominate the marketplace. In 2004,
CMS proposed expansion of the coverage of oncological
PET based on a new policy called Bcoverage with evi-
dence development^ (CED) that allowed coverage of
promising drugs, biologicals, devices, diagnostics and
procedures in order to evaluate their clinical benefit for
a limited time. As a result, the National Oncologic PET
Registry (NOPR) was formed to assess the effect of PET
on referring physicians’ intended patient management
across a wide spectrum of cancer indications for PET
not then covered by CMS.
NOPR is funded by charging the PET facilities a fee of
US$50 for each patient placed on the registry. Participating
clinicians complete a pre-PET and a post-PET questionnaire
to determine whether the imaging changed their intended
patient management. The data that NOPR collected from
2006 to 2013 demonstrated that PET changed the intended
management in about 40 % of patients overall [18]. When
used for monitoring chemotherapy, the treatment was altered
in about 78 % of patients when PET indicated that the pa-
tients’ disease was getting worse [19]. Based on the NOPR
results and the expanding literature on the efficacy of PET,
CMS expanded PET coverage for diagnosis and initial stag-
ing for most cancers in 2009 and further expanded coverage
for other indications, such as treatment monitoring, restaging
and detection of suspected recurrence, in 2013 [20].
The NOPR observational studies reflect Breal-world^
clinical practice with modern PET/CT systems and are
based on large patient cohorts. However, these studies
lack control groups and look at the change in intended
patient management based on PET results rather than
actual patient management. The new Imaging Dementia
- Evidence for Amyloid Scanning (IDEAS) study, another
CMS coverage with evidence development study in the
US, will take a more rigorous approach by evaluating
whether brain amyloid PET findings lead to a changes
in actual patient management and improvements in
outcomes. It will use Medicare claims to identify concur-
rent propensity-matched controls who have not had amy-
loid PET imaging for comparison with the study partici-
pants. Another innovative aspect of the IDEAS study is
that the three industrial providers of amyloid radiophar-
maceuticals are collaborating to finance the trial. Both
NOPR and IDEAS have the merit of overcoming cover-
age barriers by revising the way imaging technologies are
clinically evaluated.
For evaluation of PET radiopharmaceuticals, the rigid
obligation to use randomized controlled trials is expen-
sive, not always effective, and sometimes not even feasi-
ble [21]. When evaluating the clinical benefit of PET/CT,
it is important first to distinguish between direct and in-
direct clinical benefits [21]. If PET/CT can replace an
alternative invasive procedure, such as surgical staging,
then it has the direct clinical benefit of avoiding side
effects from the invasive procedure. In such cases, nonin-
vasive PET/CT could be performed in addition to the
standard invasive procedure in each patient, in order to
confirm that its diagnostic accuracy is as good as that of
the standard. Accuracy studies are well-suited to showing
the impact on patient management; there is no need to
consider long-term health outcomes with a randomized
clinical trial. If instead PET/CT replaces another imaging
modality, it has no direct benefit. It has an indirect benefit
if it provides both improved diagnostic accuracy and
changes in patient management that lead to improved
health outcomes. When assessing PET/CT for an indirect
clinical benefit, decision modelling should be used initial-
ly. If decision modelling is inconclusive, then randomized
clinical trials should be initiated that focus from the outset
on whether PET/CT improves health outcomes such as
quality of life.
Finally, continuous training efforts involving all stake-
holders in the decision-making process and actual refer-
ral and acquisition procedures should take place. Such
training can benefit from adapting successful national
or societal educational concepts from other countries.
Here, the scientific associations, such as the European
Society of Radiology and the European Association of
Nuclear Medicine can provide organizational support
and governance, as laid out several years ago in a joint
white paper [22, 23].
Any change in patient management that leads to the avoid-
ance or discontinuation of an ineffective therapy can be con-
sidered as a Bsurrogate^ for an improved health outcome.
CED has the potential to become the standard approach for
evaluating new radiopharmaceuticals and technologies to fa-
cilitate the collection of clinically valuable data. In this way,
PET/CT can be made widely available for proven oncology
indications based on appropriate evidence of its clinical value
and cost-effectiveness.
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